Elevated Serum or Plasma Sodium
Excessive parenteral sodium administration in an unconscious patient whose thirst mechanism is absent.
Excessive use of diuretics or other drugs leading to water loss in the patient who cannot compensate by intake of water.
Diabetes insipidus may be central (neurogenic), acquired nephrogenic, or congenital nephrogenic.
Mineralocorticoid or glucocorticoid excess from primary hyperaldosteronism and Cushing syndrome with or without ectopic adrenocorticotropic hormone (ACTH) production.
Insensible water loss through the skin in the patient unable to obtain water or swallow.
Clinical findings progress from somnolence to confusion, coma, and respiratory paralysis as the hypernatremia worsens.
Commonly Encountered Situations
Hypernatremia most frequently occurs in an ICU when excess intravenous (IV) sodium is given to an unconscious patient.
Suggested Additional Lab Testing
Urinary electrolytes to assess for diabetes insipidus.
Serum aldosterone to identify primary hyperaldosteronism 24-hour urine free cortisol to identify Cushing syndrome, with or without ectopic ACTH production.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Duvelisib Delayed Progression in CLL/SLL: Study
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Lenalidomide Induces Immunity, Produces Clinical Response in CLL
- Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia